Abstract
Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Current Drug Targets
Title:Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation
Volume: 14 Issue: 2
Author(s): Stelios Loukides, Konstantinos Bartziokas, Jorgen Vestbo and Dave Singh
Affiliation:
Keywords: Systemic inflammation, COPD, anti-inflammatory agents, statins, macrolides, phosphodiesterase inhibitors
Abstract: Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumilast which provides additional clinical benefit either as a single agent or as an additive treatment to long-acting bronchodilators. The second approach involves novel strategies using drugs licensed for other indications, such as statins and macrolides; limited prospective studies on these strategies exist at the moment. A third potential approach involves novel agents whose mechanism of action is closely related to COPD mechanisms and pathophysiology. Such novel treatments are of great interest since they may treat both COPD and co-morbidities. Several novel agents are currently under development and may be of importance in the future.
Export Options
About this article
Cite this article as:
Loukides Stelios, Bartziokas Konstantinos, Vestbo Jorgen and Singh Dave, Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020008
DOI https://dx.doi.org/10.2174/1389450111314020008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Inhaled Corticosteroids on the Natural History of Asthma in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sequence Variants of the Ligand-Binding Domain of the Glucocorticoid Receptor Gene and their Functional Consequences on the Three- Dimensional Protein Structure
Current Medicinal Chemistry Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA
Current Pharmaceutical Design Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Industrial Chemicals and Acute Lung injury with a Focus on Exposure Scenarios
Current Respiratory Medicine Reviews Mast Cells as Critical Effectors of Host Immune Defense against Gram-negative Bacteria
Current Medicinal Chemistry Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Propranolol Safety Profile in Children
Current Drug Safety Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Leukotrienes and Atherosclerosis
Current Drug Targets Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Meet Our Editorial Board Member
Current Organic Synthesis Oxidative Stress and the Use of Antioxidants for the Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Agents Targeting Ras Signaling Pathway
Current Pharmaceutical Design Hemopoietic Cells with Features of the Mast Cell and Basophil Lineages and their Potential Role in Allergy
Current Drug Targets - Inflammation & Allergy Navigating Alzheimer’s Disease via Chronic Stress: The Role of Glucocorticoids
Current Drug Targets C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews